Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant durvalumab with cisplatin + gemcitabine for operable urothelial cancer
2017-003565-10Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in transitional cell carcinoma (TCC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Event-free survival at 2 years. Started Nov 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-003565-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003565-10.